JPWO2020109957A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2020109957A5
JPWO2020109957A5 JP2021529335A JP2021529335A JPWO2020109957A5 JP WO2020109957 A5 JPWO2020109957 A5 JP WO2020109957A5 JP 2021529335 A JP2021529335 A JP 2021529335A JP 2021529335 A JP2021529335 A JP 2021529335A JP WO2020109957 A5 JPWO2020109957 A5 JP WO2020109957A5
Authority
JP
Japan
Prior art keywords
acid
administration
furoate
topical
carotene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021529335A
Other languages
Japanese (ja)
Other versions
JP2022509174A (en
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2019/060094 external-priority patent/WO2020109957A1/en
Publication of JP2022509174A publication Critical patent/JP2022509174A/en
Publication of JPWO2020109957A5 publication Critical patent/JPWO2020109957A5/ja
Pending legal-status Critical Current

Links

Claims (4)

式I:
Figure 2020109957000001
(式中、RHは独立して、
Figure 2020109957000002
、カプリル酸、1-ヒドロキシ-2-ナフトエ酸、2,2-ジクロロ酢酸、2-ヒドロキシエタンスルホン酸、2-オキソグルタル酸、4-アセトアミド安息香酸、4-アミノサリチル酸、酢酸、アジピン酸、アスコルビン酸、アスパラギン酸、ベンゼンスルホン酸、安息香酸、樟脳酸、カンファー-10-スルホン酸、カプリン酸(デカン酸)、カプロン酸(ヘキサン酸)、炭酸、桂皮酸、クエン酸、シクラミン酸、ドデシル硫酸、エタン-1,2-ジスルホン酸、エタンスルホン酸、ギ酸、フマル酸、ガラクタル酸、ゲンチジン酸、グルコヘプトン酸、グルコン酸、グルクロン酸、グルタミン酸、グルタル酸、グリセロリン酸、グリコール酸、馬尿酸、臭化水素酸、イソ酪酸、乳酸、ラクトビオン酸、ラウリン酸、マレイン酸、リンゴ酸、マロン酸、マンデル酸、メタンスルホン酸、ナフタレン-1,5-ジスルホン酸、ナフタレン-2-スルホン酸、ニコチン酸、硝酸、オレイン酸、シュウ酸、パルミチン酸、パモ酸、リン酸、プロピオン酸、ピログルタミン酸、サリチル酸、セバシン酸、ステアリン酸、コハク酸、硫酸、酒石酸、チオシアン酸、トルエンスルホン酸、ウンデシレン酸、ω3脂肪酸、αリノール酸、αリノレン酸、ω6脂肪酸、n-アセチルシステイン(nac)、フロエート、フロ酸メチル、フロ酸エチル、アミノカプロン酸、カプリル酸、αリポ酸、R-リポ酸、ミリスチン酸、ミリストレイン酸、パルミトレイン酸、リン脂質、ホスファチジルコリン、エライジン酸、リノール酸、リノレン酸、メントール、レチノイン酸、ビタミンA、レチノール、リノールエライジン酸、アラキドン酸、レチナール、イソトレチノイン、クルクミン、トレチノイン、α-カロテンβ-カロテン、d2エルゴステロール、エルゴカルシフェロール、7-デヒドロコレステロール、コレカルシフェロール、25-ヒドロキシコレカルシフェロール、カルシトリオール(1,25-ジヒドロキシコレカルシフェロール)、カルシトロン酸、d4ジヒドロエルゴカルシフェロール、アルファカルシドール、ジヒドロタキステロール、カルシポトリオール、タカルシトール、パリカルシトール、トコフェロール、ナフトキノン、フィロキノン(k1)、メナキノン(k2)、メナジオン(k3)、メナジオール(k4)、チアミン、アセフルチアミン、アリチアミン、ベンフォチアミン、フルスルチアミン、オクトチアミン、プロスルチアミン、スルブチアミン、リボフラビン、ナイアシン、ニコチンアミド、パントテン酸、デクスパンテノール、パンテチン、ピリドキシン、リン酸ピリドキサール、ピリドキサミン、ピリチノール、ビオチン、葉酸、ジヒドロ葉酸、フォリン酸、レボメフォリック酸、アデノシルコバラミン、シアノコバラミン、ヒドロキソコバラミン、メチルコバラミン、コリン、デヒドロアスコルビン酸、又は1-ドコサノールを表す)の化合物、並びにその薬学的に許容可能な水和物、溶媒和物、鏡像異性体、及び立体異性体。
Formula I:
Figure 2020109957000001
(wherein RH is independently
Figure 2020109957000002
, caprylic acid, 1-hydroxy-2-naphthoic acid, 2,2-dichloroacetic acid, 2-hydroxyethanesulfonic acid, 2-oxoglutaric acid, 4-acetamidobenzoic acid, 4-aminosalicylic acid, acetic acid, adipic acid, ascorbic acid , aspartic acid, benzenesulfonic acid, benzoic acid, camphoric acid, camphor-10-sulfonic acid, capric acid (decanoic acid), caproic acid (hexanoic acid), carbonic acid, cinnamic acid, citric acid, cyclamic acid, dodecyl sulfate, ethane -1,2-disulfonic acid, ethanesulfonic acid, formic acid, fumaric acid, galactaric acid, gentisic acid, glucoheptonic acid, gluconic acid, glucuronic acid, glutamic acid, glutaric acid, glycerophosphoric acid, glycolic acid, hippuric acid, hydrobromic acid , isobutyric acid, lactic acid, lactobionic acid, lauric acid, maleic acid, malic acid, malonic acid, mandelic acid, methanesulfonic acid, naphthalene-1,5-disulfonic acid, naphthalene-2-sulfonic acid, nicotinic acid, nitric acid, olein Acid, oxalic acid, palmitic acid, pamoic acid, phosphoric acid, propionic acid, pyroglutamic acid, salicylic acid, sebacic acid, stearic acid, succinic acid, sulfuric acid, tartaric acid, thiocyanic acid, toluenesulfonic acid, undecylenic acid, omega-3 fatty acids, α-linol acid, alpha-linolenic acid, omega-6 fatty acid, n-acetylcysteine (nac), furoate, methyl furoate, ethyl furoate, aminocaproic acid, caprylic acid, alpha-lipoic acid, R-lipoic acid, myristic acid, myristoleic acid, palmitolein acid, phospholipids, phosphatidylcholine, elaidic acid, linoleic acid, linolenic acid, menthol, retinoic acid, vitamin A, retinol, linoleic elaidic acid, arachidonic acid, retinal, isotretinoin, curcumin, tretinoin, α-carotene, β-carotene, d2 Ergosterol, ergocalciferol, 7-dehydrocholesterol, cholecalciferol, 25-hydroxycholecalciferol, calcitriol (1,25-dihydroxycholecalciferol), calcitronic acid, d4 dihydroergocalciferol, alphacalcidol, dihydro tachysterol, calcipotriol, tacalcitol, paricalcitol, tocopherol, naphthoquinone, phylloquinone (k1), menaquinone (k2), menadione (k3), menadiol (k4), thiamine, acefluthiamine, allithiamine, benfotiamine, flu sultiamine, octoti Amine, prosultiamine, sulbutiamine, riboflavin, niacin, nicotinamide, pantothenic acid, dexpanthenol, pantethine, pyridoxine, pyridoxal phosphate, pyridoxamine, pyritinol, biotin, folic acid, dihydrofolic acid, folinic acid, levomefolic acid, adenosylcobalamin , cyanocobalamin, hydroxocobalamin, methylcobalamin, choline, dehydroascorbic acid, or 1-docosanol), and pharmaceutically acceptable hydrates, solvates, enantiomers, and stereoisomers thereof.
請求項1に記載の化合物と薬学的に許容可能な担体とを含む医薬組成物。 A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier. 局所点眼剤、局所ペースト、眼科用溶液、薬物送達デバイス、経口投与、頬内投与、経直腸投与、局所投与、経皮投与、経粘膜投与、トローチ、噴霧剤、静脈内投与、経口溶液、鼻内噴霧剤、クリーム、皮膚軟膏、ゲル、ローション、懸濁液、口腔噴霧剤、頬粘膜層用錠剤、非経口投与、シロップ、又は注射のために配合されている、請求項に記載の医薬組成物。 topical eye drops, topical pastes, ophthalmic solutions, drug delivery devices, oral administration, buccal administration, rectal administration, topical administration, transdermal administration, transmucosal administration, lozenges, sprays, intravenous administration, oral solutions, nasal 3. A medicament according to claim 2 , formulated for internal spray, cream, skin ointment, gel, lotion, suspension, mouth spray, buccal layer tablet, parenteral administration, syrup or injection. Composition. 構造:
Figure 2020109957000003
の化合物。
structure:
Figure 2020109957000003
compound.
JP2021529335A 2018-11-26 2019-11-23 Ophthalmic compositions and methods for the treatment of skin and eye diseases Pending JP2022509174A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
IN201841044540 2018-11-26
IN201841044540 2018-11-26
IN201941001491 2019-01-12
IN201941001491 2019-01-12
PCT/IB2019/060094 WO2020109957A1 (en) 2018-11-26 2019-11-23 Ophthalmic compositions and methods for the treatment of skin diseases and eye diseases

Publications (2)

Publication Number Publication Date
JP2022509174A JP2022509174A (en) 2022-01-20
JPWO2020109957A5 true JPWO2020109957A5 (en) 2022-12-02

Family

ID=70852834

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021529335A Pending JP2022509174A (en) 2018-11-26 2019-11-23 Ophthalmic compositions and methods for the treatment of skin and eye diseases

Country Status (12)

Country Link
US (1) US20220033360A1 (en)
EP (1) EP3860592A4 (en)
JP (1) JP2022509174A (en)
KR (1) KR20210095907A (en)
AU (1) AU2019390704A1 (en)
BR (1) BR112021009700A2 (en)
CA (1) CA3121138A1 (en)
IL (1) IL282898A (en)
MX (1) MX2021005442A (en)
SG (1) SG11202104410SA (en)
WO (1) WO2020109957A1 (en)
ZA (1) ZA202102872B (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220104040A (en) * 2019-11-25 2022-07-25 센터 포 인텔리전트 리서치 인 크리스탈 엔지니어링, 에스.엘. Co-crystals of steroid and secosteroid compounds and compositions comprising them

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8697109B2 (en) * 2000-08-16 2014-04-15 Encore Health, Llc Caged mercaptan and seleno-mercaptan compounds and methods of using them
US20050196418A1 (en) * 2004-03-04 2005-09-08 Yu Ruey J. Bioavailability and improved delivery of alkaline pharmaceutical drugs
US20120208858A1 (en) * 2011-02-15 2012-08-16 Allergan, Inc. Pharmaceutical Cream Compositions of Oxymetazoline and Methods of Use
US20120225918A1 (en) * 2011-03-03 2012-09-06 Voom, Llc Compositions and Methods for Non-Surgical Treatment of Ptosis
AU2012281059A1 (en) * 2011-07-14 2014-02-06 Allergan, Inc. Gel compositions of oxymetazoline and methods of use
KR101586789B1 (en) * 2012-12-28 2016-01-19 주식회사 종근당 Sustained-release lipid pre-concentrate of cationic pharmacologically active substance and pharmaceutical composition comprising the same
WO2014158119A1 (en) * 2013-03-29 2014-10-02 Santa Farma İlaç Sanayi̇ A.Ş Aqueous solution composition containing ipratropium and oxymetazoline

Similar Documents

Publication Publication Date Title
RU2019123515A (en) COMPOSITIONS AND METHODS FOR TREATMENT OF CHRONIC PAIN
US20220279831A1 (en) Compositions, kits and methods for nutrition supplementation
US8168611B1 (en) Compositions, kits and methods for nutrition supplementation
US20130084272A1 (en) Compositions, kits and methods for nutritional supplementation with twelve carbon chain fatty acids and twelve carbon chain acylglycerols
JPWO2020109957A5 (en)
US20170202802A1 (en) Compositions, kits and methods for nutrition supplementation
RU2021114450A (en) OPHTHALMIC COMPOSITIONS AND METHODS FOR THE TREATMENT OF SKIN AND EYE DISEASES
US20110251151A1 (en) Combination compositions for reducing intraocular pressure
US20190021385A1 (en) Orally dissolvable compositions for nutrition supplementation
JP2006506361A5 (en)
US20110245193A1 (en) Combination compositions for reducing intraocular pressure
US10905650B2 (en) Gummy compositions for nutritional supplementation
US20150290128A1 (en) Gummy compositions for nutritional supplementation
RU2021107452A (en) OPHTHALMIC COMPOSITIONS AND METHODS FOR THE TREATMENT OF VISUAL DISORDERS AND SKIN DISEASES
EP3793522A1 (en) Compositions and methods for the treatment of inflammatory skin diseases and cancer
US20220033360A1 (en) Ophthalmic compositions and methods for the treatment of skin diseases and eye diseases
WO2020044136A1 (en) Ophthalmic compositions and methods for the treatment of eye disorders and skin diseases
CN220299601U (en) Adjustable conveying device for medicine supplement
US20150305386A1 (en) Compositions for nutritional supplementation
WO2021245503A1 (en) Process for the preparation of eflornithine derivatives and their pharmaceutical acceptable salts thereof